Replies to post #93731 on Biotech Values

[DonShimoda]

Thanks, Peter. I must have read the article but for the life of me I don't remember it...must be getting old. As you point out, pre-clinical is a long ways from first line treatment but it's nice to know that, after a series of starts and stops, ariad appears to be heading in the right direction.

fwiw, my take on rida is that it's potentially a lot more valuable to MRK in combination with several of their drug candidates (namely MK-0646 and MK-2206) than it is as a stand alone drug. That's why I'm hoping to see a restructuring of the partnership that results in additional cash for ariad. In the Barclays presentation, Berger was adamant that they wouldn't be doing another secondary...a refreshing change from the past now that the ceo has $3mm of his own money on the line.